L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 10/31/2018 |
| Start Date: | August 2013 |
| End Date: | January 2019 |
Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level
The major impact of this study will be to identify the adult severe asthma cohort that will
benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of
adult severe asthma patients will respond to supplemental L-arginine and derive clinical
benefit from the addition of this therapy to standard-of-care asthma medications. The
investigators hypothesize that the patients that benefit most will have low exhaled nitric
oxide concentrations (< 20 ppb) at baseline.
benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of
adult severe asthma patients will respond to supplemental L-arginine and derive clinical
benefit from the addition of this therapy to standard-of-care asthma medications. The
investigators hypothesize that the patients that benefit most will have low exhaled nitric
oxide concentrations (< 20 ppb) at baseline.
We hypothesize that a subset of adult severe asthma patients will respond to supplemental
L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care
medications. We hypothesize that these patients will have lower exhaled NO concentrations
(<20 ppb) and lower nitric oxide synthase 2 (NOS2)/ arginase I (Arg1) mRNA ratios in their
airway epithelial cells than "non-responders." The aim is to test the hypothesis that adult
severe asthma subjects with exhaled breath NO concentrations < 20 ppb will have fewer
American Thoracic Society (ATS)-defined asthma exacerbations over 3 months when treated with
L-arginine compared to subjects with exhaled nitric oxide concentration (FeNO) > 25 ppb. The
major impact of this study will be to identify the adult severe asthma cohort that will
benefit from supplemental L-arginine therapy to define the underlying mechanisms of arginine
benefit in asthma. This follows our initial 20 subject trial of L-arginine in asthma subjects
(Kenyon et al., Pharmaceuticals 2011) that was designed to determine how L-arginine was
metabolized (by testing serum markers) and whether certain participants had clinical benefit.
To do this, we will recruit a total of 50 ATS-defined severe asthmatic subjects with ongoing
asthma exacerbations in past two months and enroll them in a randomized, blinded,
placebo-controlled, cross-over designed trial of L-arginine and placebo. We will compare 25
subjects with "low" FeNO < 20 with 25 subjects that have "high" FeNO > 25 ppb.
L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care
medications. We hypothesize that these patients will have lower exhaled NO concentrations
(<20 ppb) and lower nitric oxide synthase 2 (NOS2)/ arginase I (Arg1) mRNA ratios in their
airway epithelial cells than "non-responders." The aim is to test the hypothesis that adult
severe asthma subjects with exhaled breath NO concentrations < 20 ppb will have fewer
American Thoracic Society (ATS)-defined asthma exacerbations over 3 months when treated with
L-arginine compared to subjects with exhaled nitric oxide concentration (FeNO) > 25 ppb. The
major impact of this study will be to identify the adult severe asthma cohort that will
benefit from supplemental L-arginine therapy to define the underlying mechanisms of arginine
benefit in asthma. This follows our initial 20 subject trial of L-arginine in asthma subjects
(Kenyon et al., Pharmaceuticals 2011) that was designed to determine how L-arginine was
metabolized (by testing serum markers) and whether certain participants had clinical benefit.
To do this, we will recruit a total of 50 ATS-defined severe asthmatic subjects with ongoing
asthma exacerbations in past two months and enroll them in a randomized, blinded,
placebo-controlled, cross-over designed trial of L-arginine and placebo. We will compare 25
subjects with "low" FeNO < 20 with 25 subjects that have "high" FeNO > 25 ppb.
Inclusion Criteria:
- Adults >18 yrs of age
- Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am
J Respir Crit Care Med 2000; 162:2341)
- Active asthma medications of high dose inhaled corticosteroids plus long-acting beta
agonist
- History of recent asthma exacerbations or Asthma control test score < 20/25
Exclusion Criteria:
- <19 yrs of age
- Forced expiratory volume 1sec <30% predicted
- Pregnant or nursing women
- Current smokers or smoking history > 15 pack years
- Actively taking or known intolerance to L-arginine
We found this trial at
1
site
Click here to add this to my saved trials
